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Abstract Oligometastasis is a cancer disease state char-
acterized by a limited number of metastatic tumors
involving single or few organs and with biological prop-
erties that make them potentially amenable to locoregional
antitumor therapy. Current clinical data show that they are
potentially curable with surgical resection or/and radio-
therapy. Yet, mechanisms of progression from primary
tumor to oligometastasis, rather than to polymetastases, is
lacking in detail. In the current review we focus on the role
of micro-RNAs in the regulation of metastases develop-
ment and the role they may play in the differentiation of
oligometastatic from polymetastatic progression. We also
discuss the analyses of metastatic samples from oligo-and
polymetastatic patients, which suggest that oligometastasis
is a distinct biologic entity regulated in part by micro-
RNAs. In addition, a review of the known functions of
oligometastatic-specific micro-RNAs suggest that they
regulate multiple steps in the metastatic cascade, including
epithelial–mesenchymal transition, tumor invasion, in-
travasation, distant vascular extravasation and proliferation
in a distant organ. Understanding the role of micro-RNAs
and their target genes in oligometastatic disease may allow
for the development of targeted therapies to effectively
conrol the spread of metastases.
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Introduction
Current approaches to the staging of cancer patients are
based on the separation of primary or locoregional disease
and distant metastases. Such separation depends on the
ability to apply curative surgical or radiotherapy approa-
ches to the primary tumors or locoregional disease, while
distant metastases are commonly treated by palliative
systemic therapy [1, 2]. The heterogeneity of metastatic
spread is generally underestimated and many clinical reg-
imens are not based on the extent of metastatic dissemi-
nation. The term ‘‘oligometastases’’ was introduced in
1995 and describes an intermediate state of metastatic
spread between localized disease and diffuse metastases
[3]. The initial definition of oligometastases was introduced
mostly based on the limited number of secondary lesions,
but more recently, the rate of metastases development was
taken in consideration with introduction of the concept of
‘‘oligorecurrence’’ [4–6]. The concept of oligometastatic
disease has significant clinical value because a limited
number of lesions can be treated with the same potentially
ablative approaches as spatially confined primary tumors.
Previously, the feasibility of this approach was demon-
strated mostly with surgical intervention in limited number
of cancers [7, 8]. More recently, rapid advances in imaging
techniques and stereotactic body radiotherapy (SBRT)
allow earlier detection of oligometastases and non-invasive
or minimally invasive intervention in cancers with different
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histologies and different secondary sites [9–11]. Results
from large-scale randomized controlled studies are not
available, but recent comprehensive reviews of the litera-
ture suggest that approximately 20% of patients may rep-
resent an oligometastatic phenotype where local treatment
of metastases by resection, ablation or radiotherapy yields
outcomes that are substantially improved when compared
to non-treated patients [12–15]. Yet, little is known so far
about the molecular basis of oligometastases and the
pathways that can be responsible for differentiating
between polymetastatic or oligometastatic spread.
In the current report we discuss the potential role of
micro-RNAs in oligometastatic disease based on known
examples of regulation of the metastatic cascade by micro-
RNAs, along with our initial investigations of micro-RNA
expression in the secondary lesions of oligometastatic and
polymetastatic patients.
Oligometastases versus polymetastases: are there
genome-driven mechanisms?
Despite advances in the understanding of the clinical sig-
nificance of oligometastasis, comparative molecular and
genomic investigations of oligometastatic and polymeta-
static lesions are limited. Two extreme possibilities
implicate either a clonal origin with inherited molecular
and phenotypic differences of oligo-or polymetastases, or
sequential development of the metastatic process with
oligometastases as an early but transient phase of poly-
metastatic disease (Fig. 1). Current data based on genomics
approaches are consistent with both suggestions. The clo-
nal nature of metastases and their origin from topographi-
cally and genetically distinct regions of tumors has been
demonstrated in the next-generation sequencing of the
primary and secondary tumor samples taken from the same
patients [16–18]. Distinct geographic regions of primary
pancreatic tumors represented different clonal structure and
gave origin to the distinct metastatic clones [16, 17]. In
clear-cell renal carcinoma it was demonstrated that meta-
static clones could share common mutational events with
ancestor clones in the primary tumor [19]. In breast cancer,
application of single-cell sequencing approaches revealed a
clonal sub-structure of primary tumors and the initiation of
liver metastases as the result of expansion of individual
primary clones [18, 20]. These studies demonstrated that
secondary tumors are derived from individual clones of
heterogeneous primary tumors and follow the rules of
Darwinian evolution [21, 22]. Therefore it is reasonable to
suggest that secondary lesions with an oligometastatic
phenotype may originate from the tumor clones with
genetic properties different from clones potentially ‘‘pro-
grammed’’ towards polymetastatic dissemination.
Detection of these differences can be pivotal in identifying
prognostic/predictive markers of metastatic disease and
detection of new therapy targets. In addition, constant
evolution and ‘‘re-seeding’’ have been demonstrated [17,
23]. This raises the possibility that oligometastases may be
a transient stage of general metastatic progression (Fig. 1).
The time scale of spontaneous metastases development,
estimated from genomic differences between matched
primary and secondary tumors, varies between 1 year to 5
decades [24], providing a variety of opportunities for the
evolution from restricted oligometastatic clones to dis-
seminated disease either through tertiary metastases or
progressive evolution of the primary tumor [17]. Genomic
and transcriptomic profiling of oligo-and polymetastatic
lesions may reveal recurrent mutations/patterns common
for both types of secondary tumors or identify distin-
guishing characteristics that separate biologic processes
responsible for distinct phenotypes.
Multi-step nature of metastatic cascades as the basis
for differences in oligo-and polymetastatic progression
Based on advances of high-throughput genomic, tran-
scriptomic and proteomic approaches, the last decade has
brought important breakthroughs in our understanding of
the metastasis process. It is commonly accepted now that
metastases formation is a multi-step process with defined
steps (Fig. 2). Understanding of the specific biological
processes and pathways underlying each step is rapidly
evolving (reviewed in [25–28]). This multi-step nature of
metastatic cascades suggests that divergence between
oligometastases and polymetastases may be initiated on
different steps of metastases development. Each step can
provide a bifurcation between the evolutionary pathways of
these metastatic types, though it is possible to speculate
that bifurcations in the earlier steps (such as invasion/
remodeling, Fig 2b) can lead to more pronounced differ-
ences between oligo-and polymetastatic phenotypes as
compared with bifurcations at the later steps (Fig. 2g, h).
This multi-step nature of metastatic cascades can induce
heterogeneity even within these two metastatic phenotypes.
Indeed, recently Tree et al. [12] noticed that at least three
different cohorts of patients were reported as oligometa-
static: those who present at time of diagnosis with oligo-
metastatic disease (‘‘synchronous’’ oligometastases), those
who had truly oligometastatic relapse after curative loco-
regional therapy of primary disease (metachronous olig-
ometastases) and those with ‘‘induced’’ oligometastases
after cytoreductive therapy. These groups probably have
different prognoses and benefit from different therapeutic
approaches. Detailed investigations of these steps in
the context of oligometastases and polymetastases
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development are necessary for detection of prognostic
markers and potential therapeutic targets with potential
clinical applications.
Examination of biological processes implicated in the
different stages of metastases development leads to an
important conclusion: if the most prominent hallmark of
cancer growth—sustained proliferation [29]—is critical for
the development of primary tumors and advanced coloni-
zation (Fig. 2a, h), all intermediate steps of metastases
development are based on the processes not directly related
to the regulation of tumor growth. Rather, they involve
multiple interactions of metastatic cells with microenvi-
ronment either through direct heterotypic cell–cell and
cell–ECM contacts (as in steps 2b–2f) or formation of
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Fig. 2 Multiple steps of metastases development and role of micro-
RNA in their regulation. Sequential steps of metastases development
are presented based on the current reviews [25, 26, 28, 51]. Note that
final selection of metastatic clones can lead to the formation of radio/
chemoresistant secondary tumors, as was described elsewhere [33],
presumably due to selection against cytotoxic factors of host
microenvironment (see g–h). Boxes below diagram represent major
functions involved in each step, while boxes above illustrate some
micro-RNAs involved in the regulation of each step (see text for
explanations and references)
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multiple paracrine and autocrine loops between tumor and
stromal cells via secreted ligands and their cognate
receptors (Fig. 2g) [30, 31, 32]. Of note, formation of these
auto-paracrine loops is often associated with development
of tumor clones resistant to genotoxic stress [33–36]. These
processes involve constant alterations of the cytoskeleton
and cell architecture associated with motility, invasion and
circulation in blood. This suggests that metastases devel-
opment might be regulated through mechanisms different
from traditional oncogenic signaling, and instead adopted
to the tumor plasticity typical for metastatic cascades.
Accumulating evidences indicate that one of the most
important mechanisms of regulation of the broad set of
pathways involved in metastases regulation is based on
micro-RNAs.
Micro-RNAs as systemic regulators of metastases
development
MicroRNAs (miRs) are small (19–22 nucleotide) RNAs
involved in the regulation of gene expression. A full
description of the biogenesis and complex functions of
miRs is beyond the scope of this review and is available
elsewhere [37–39]. Briefly, precursors of miRs are encoded
by intronic regions of protein encoding genes or by RNA
encoding regions of the genome known as primary mi-
croRNAs (pri-miRs). They are processed and translocated
into the cytoplasm in the form of double-stranded stem-
loop structures known as precursor microRNAs (pre-miRs)
with the involvement of multiple nucleases including the
Drosha, Dicer and Argonaut families (Fig. 2). Importantly,
recent investigations detected systemic changes in micro-
RNA processing, with imbalance between pre-miRs and
mature miRs, and between 3p and 5p mature miRs, due to
Ago2 protein modifications by EGFR and other regulators
[40, 41] in addition to tumor-related somatic mutations of
Dicer1 [42]. Suppression of Ago2 can lead to the decrease
of the ratio of mature miRs to stem-loop precursors, while
mutations in Dicer1 are associated with the decrease of 5p
to 3p ratio of mature single-stranded miRs (Fig. 3). These
observations indicate that functional or mutational changes
of single proteins involved in the processing of miRs can
affect hundreds of down-stream genes. They also indicate
that in the analysis of micro-RNA expression, it is impor-
tant to account for the balance between pre-miRs and
mature miRs and the balance between 5p and 3p mature
miRs. Each mature single-stranded miR binds to target
mRNAs through complimentary seed sequences 6 to 8
nucleotides in length. Longer mRNA complimentary sites
and the presence of adenosine immediately 5’ of the site
may increase mRNA suppression (reviewed in [43] ). Upon
binding, primarily to the 3’ untranslated region (UTR) of
the mRNA, miRs induce either suppression of mRNA
translation or degradation of the mRNA itself. Each miR is
able to bind to hundreds of target mRNAs, thus they rep-
resent a potent group of regulators of gene expression.
Micro-RNAs’ extensive regulatory ability has engen-
dered intensive investigation in the context of metastases
development. Micro RNAs can mediate the formation of
the flexible networks involved in the regulation of the
multistep metastatic cascades. Micro-RNAs have also been
shown to be regulated by p53 and myc, leading to either
inhibition or activation of pro-survival mechanisms nec-
essary for initial proliferation of the primary tumor [44].
This step can also be modulated by regulation of DNA
repair and epigenetic modifications to DNA by micro-
RNAs, and the converse regulation of micro-RNAs by
these mechanisms, as has been highlighted in cancers with
micro-satellite instability [45].
Proceeding along the metastatic cascade, many micro-
RNAs have been implicated in regulation of epithelial to
mesenchymal transition (EMT). One of the most studied
families of micro-RNAs is the miR-200 family, which has
been implicated with the maintenance of an epithelial
phenotype (preventing EMT) via its gene targets Zeb1 and
Zeb2, the transcriptional suppressors of E-cadherin [46, 47,
48]. This suppression prevents cancer cells in primary
tumors from initiating the process of metastasis. Mir-205 is
also implicated in EMT suppression through a feedback
loop between Zeb1 and TGFB1 [49]. A similar function
can be performed by mir-203 through formation of nega-
tive feedback loop with Snail [50]. It is clear that epithelial
cell plasticity plays an important role in metastatic cas-
cades, and the role of other micro-RNAs in this process is
under intensive investigations as detailed below.
Concurrent with EMT is invasion of tumor cells through
the basement membrane, a process extensively regulated
by many micro-RNAs through regulation of Rho-mediated
actin cytoskeleton regulation, integrin-mediated cell-cell
adhesion and alterations in the extra-cellular matrix itself
(reviewed in [51]). Another well-studied example of reg-
ulation at this step is miR-31, which suppresses invasion/
migration of tumor cells, thereby suppressing the initial
stages of metastases [52]. Proceeding along the metastatic
cascade, the step of adhesion in the second site is critical
for determination of site-specificity of a given tumor.
Interestingly, due to the targeting of RhoA and ITGA5,
miR-31 is critical in adhesion of circulating tumor cells,
therefore providing one of the few known ‘‘master on-
comirs’’ [52]. Similarly, miR-214 through suppression of
AP2-transcription factor TFAP2C and Integrin alpha-3, can
also promote both invasion and survival in anoikis [53].
This step of survival in circulation can also be promoted by
miR-26a through Rb1-E2F1 pathway [54]. Some examples
of metastases-related miRs are presented in Fig. 2. The
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final stages of metastases formation include initial coloni-
zation and subsequent proliferation in distant sites. These
steps involve multiple miRs regulating the mesenchymal-
to-epithelial transition (MET), formation of a pre-meta-
static niche, adaptation of surviving tumor cells to the new
microenvironment, secondary tumor growth and angio-
genesis (Fig. 2g, h). Multiple miRs can regulate the phe-
notype of tumor cells in these stages. The oncogenic miR-
17-92 cluster can be up-regulated by c-Myc, E2F and
Hedgehog [55, 56] and suppresses thrombospondin 1,
thereby promoting angiogenesis [57]. Let-7 and miR-126
can inhibit proliferation through HMGA2 and PIK3 sig-
naling [58, 59], while the hypoxia-inducible miR-210 is
involved in mitochondria stabilization and regulation of
cell survival/proliferation (reviewed by [60]). An under-
standing of both the pro- and anti-metastatic effects of
micro-RNA regulated networks is leading to an apprecia-
tion of the role of both tumor cells and the micro-envi-
ronment in metastasis (further reviewed in [61]). These
data suggest that analysis of miRs may lead to the
identification of the biological basis of oligometastases and
perhaps differentiate between patients who are truly oli-
gometastatic or those who are at risk for widespread distant
disease.
Detection of micro-RNAs associated
with oligometastases development (oligomiRs)
As described above, microRNAs are potent regulators of
metastatic cascades, providing flexible regulatory networks
for metastases development. Yet, due to the limited number
of studies comparing oligometastatic to polymetastatic
clinical samples, little is known about their role in olig-
ometastases development. To detect microRNAs associ-
ated with oligometastases and discriminate them from
polymetastases, we investigated archival samples from two
clinical databases of oligometastatic and polymetastatic
patients [6, 62]. These investigations focused on the direct
comparison of oligo-and polymetastatic secondary lesions
Fig. 3 Processing and maturation of micro-RNAs. Genomic
sequence of primary micro-RNA (pri-miR) encodes *80 nt sequence
of the stem-loop pre-micro-RNA (Fig. 3a). This stem-loop structure
(pre-miR) is recognized and excised from transcribed RNA by
multiple proteins including Drosha and DGCR8. The stem-loop pre-
miR is exported in cytoplasm by Exportin-5/Ran-GTP complexes
(Fig. 3b) and is further processed by Ago2/Dicer1 nucleases into the
mature single-stranded 5p and 3p miRs (Fig. 3c). The 5p and 3p
mature single-stranded miRs will bind to different down-stream target
mRNAs and can lead to different functional outcomes (Fig. 3d).
Therefore the balance of micro-RNA precursors and mature forms can
determine different phenotypes of normal and tumor cells. Current
data indicate that this balance is susceptible to post-translational
modifications and/or mutations of enzymes, responsible for miRs
processing, including Ago2 and Dicer1 (Fig. 3c). These mutations
and post-translational modifications of Ago2, associated with EGFR
signaling, hypoxia and proteasome functions are described elsewhere
[18–20]
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rather than on comparison of primary and secondary
tumors. This led us to the detection of microRNA patterns
specific to oligometastatic lesions and suggested the dif-
ferential regulation of specific molecular pathways that
guide oligometastatic vs. polymetastatic development of
secondary tumors. We will further name these oligome-
tastases-specific microRNAs as oligomiRs.
Micro-RNA signatures of surgically resected lung
metastasis with oligo-and polymetastatic progression
Sixty-three patients with available metastatic samples were
considered oligometastatic at the time of pulmonary
resection, with 5 or less metastases. Based on the analysis
of recurrence patterns in the lung following resection, 32
patients were designated as slow progressors, correspond-
ing to the oligometastatic phenotype and 16 were classified
as rapid progressors, corresponding to the polymetastatic
phenotype. These patients had dramatic differences in
survival, as demonstrated by Kaplan–Meier analysis, in
favor of the slow progressors [6].
Statistical analysis revealed that 39 micro-RNAs were
differentially expressed between oligometastatic (slow
progressors) and polymetastatic (rapid progressors) sam-
ples. Only three micro-RNAs were down regulated in
oligometastases as compared to polymetastases; the
remainder were up regulated (Fig. 4b). As described
below, several miRNAs up regulated in oligometastases
have been characterized as tumor suppressors, implying
that their up-regulation may repress oncogenic genes/
pathways and limit metastatic spread (Table 1). Therefore
these experiments revealed that oligometastases of differ-
ent primary origin that develop in the same secondary site
(lungs) express patterns of tumor-suppressive micro-RNAs,
which differentiates them from polymetastases.
OligomiRs differentially expressed in patients treated
with Stereotactic Body Radiotherapy (SBRT)
Stereotactic body radiotherapy is a form of radiotherapy
that exploits advances in radiotherapy technology, com-
puting and imaging to deliver high doses of radiation to
local tumors. Patients enrolled in a clinical trial, reported
by Lussier et al. [14, 63], had diverse primary and meta-
static sites, received adjuvant therapy or/and surgery prior
to enrollment and had controlled primary tumors with five
or less metastases. Patients were classified into two groups
based on radiographic response after completion of SBRT:
polymetastatic patients had (1) progression with develop-
ment of 5 new metastatic tumors in less than 4 months
from time of first metastatic progression, or (2) progression
within a body cavity suggesting the presence of diffuse
metastatic disease. In contrast, oligometastatic patients had
either no evidence of progression or experienced progres-
sion that did not satisfy the above criteria for designation of
polymetastases. The expression patterns of micro-RNAs
from metastatic tumors correctly classified seven of nine
oligometastatic patients and five of five poly-metastatic
patients (Fig. 4b). Twenty-nine differentially expressed
oligomiRs were identified in this dataset—16 were down-
regulated and 13 up-regulated in oligometastases relative to
polymetastases (Table 1). Importantly, in five patients with
available matched primary and metastatic tumors, samples
of primary and secondary tumors were co-clustered. This
suggests that secondary tumors inherit patterns of micro-
RNAs expressed in primary tumors (Fig. 1a). On the other
hand, analysis of the primary tumors was unable to statis-
tically significantly separate the oligo-and polymetastatic
patients based on primary micro-RNA patterns. This lack
of discrimination may be due to the heterogeneity of
Fig. 4 Cross-talk between micro-RNA patterns obtained in surgical
and stereotactic body radiotherapy (SBRT) cohorts. a Only 3
overlapping micro-RNAs were identified in the surgical and SBRT
cohorts (miR-328, miR-502-5p and miR-199b-5p (Table 1). b Unsu-
pervised clustering of patients in the surgical and SBRT cohorts based
on differentially expressed micro-RNAs successfully segregated
patients with oligo-and polymetastatic disease independently on
clinical parameters of disease progression (heat maps represent
normalized CT values; green are up- and red are down-regulated
micro-RNAs). c Application of the SBRT micro-RNA signature to
surgical patients successfully separated them into oligo-and polymet-
astatic clusters (left panel); the same was true for application of the
surgery micro-RNA signature to SBRT cohort
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primary tumors, wherein the micro-RNA expression pat-
terns of those clones that can metastasize are masked by
numerous non-metastasizing clones (Fig. 1). In genetically
more homogenous metastatic tumors, these patterns can be
revealed and potentially used for prognostic/predictive
purposes. Development of micro-RNA signatures associ-
ated with types of metastases progression and/or response
to local therapy can lead to improved prognostic tools for
oligometastatic patients.
Cross-talk between oligomiRs patterns in two
independent databases
Patterns of oligomiRs detected in each cohort of patients
were able to stratify patients in oligo-and polymetastatic
phenotype independently from clinical parameters (7, 24).
In the surgery cohort, microRNA expression successfully
classified 13 of 16 (81.3%) polymetastatic patients and 20
of 32 (62.5%) oligometastatic [odds ratio = 7.22;
p = 0.006, Fisher’s exact test (FET), 24]. Similarly, in
SBRT cohort patterns of oligomiRs successfully classified
8 of 10 (80%) oligometastatic patients and 6 of 6 (100%)
polymetastatic (p = 0.007, FET, [7]). These separations
are schematically depicted in Fig. 4b. At the same time,
both patterns did not overlap significantly; only three
microRNA were common between oligomiRs from surgery
and SBRT cohorts (miR-328, miR-502-5p and miR-199b-
5p; see Fig. 4a). Yet, when we used 39 oligomiRs detected
in the surgery cohort to classify patients in the SBRT
cohort, we obtained significant separation of oligo-and
polymetastatic patients (OR = 7.2, p = 0.047, FET;
Fig. 4c). Similarly, when we applied 27 oligomiRs from
the SBRT cohort to classify patients in the surgery cohort
we observed divergence of oligo-and polymetastatic phe-
notypes (OR = 3.9, p = 0.032, FET). These findings
suggest that both sets of detected oligomiRs are actually
co-expressed in oligometastatic lesions from two inde-
pendent clinical cohorts, but cannot be simultaneously
detected due to the limited statistical power of these
smaller sample sets. Further studies incorporating larger
numbers of samples and more sensitive profiling platforms
will lead to extended list of oligomiRs commonly shared
between different clinical groups of patients.
Biological validation of clinical observations-
controversial functions of mir-200c in oligometastases
development
Detection of oligomiRs differentially expressed in olig-
ometastases as compared with polymetastases posed
questions about their functional significance. We found in
the SBRT cohort three up-regulated micro-RNAs in
polymetastases that were members of the mir-200 family
(mir-200b, mir-200c and mir-141). We suggested that if
these differentially expressed micro-RNAs are involved in
the regulation of metastatic phenotypes, their ectopic
expression in oligometastatic tumor may switch its phe-
notype to polymetastatic. To test this concept two models
were used: a syngeneic mouse melanoma B16 model with
oligo and poly-metastatic clones derived as described
elsewhere [33], and a human MB-435 breast carcinoma
model with oligo- and poly-metastatic clones selected
in vivo. Over-expression of mir-200c was sufficient to
switch the oligometastatic phenotypes to polymetastatic
phenotypes in both models. These findings indicated that
oligomiRs detected in our clinical datasets may be causal
in the regulation of oligo- vs. poly-metastatic development
(7). At the same time these were paradoxical observations,
since extensive literature indicate that mir-200c is a tumor
suppressor (Fig. 2) [26, 27]. However, our data suggested
that cells that had escaped the primary tumor were more
metastatic when expressing microRNA 200c. Currently
these results are supported by those of Dykxhoorn et al.
[64] and Korpal et al. [65], both of which demonstrated that
expression of 200c increases the metastatic phenotype in
tumor cells that escape the primary tumor by enforcing the
epithelial phenotype and/or suppressing tumor suppressive
proteins induced by Sec23a, a target of mir-200c. These
results demonstrate that micro-RNAs’ effects on metastasis
progression may be different in primary tumor and distant
metastases.
Multiple steps of the metastatic cascade are targeted
by oligometastatic miRs
Almost all of the micro-RNAs over-expressed in the sur-
gery oligometastatic samples, and many of those up-regu-
lated in the SBRT oligometastatic samples, have been
shown to be tumor-suppressors (Table 1). This suggests
that oligometastases development may be associated with
miR-based negative regulatory loops which are suppressed
in polymetastases evolution. Examination of the molecular
pathways predicted to be regulated by oligomiRs from both
datasets suggests that they may regulate proliferation,
EMT, invasion and motility through multiple down-stream
targets (Table 1). Accordingly they may be implicated into
the regulation of the distinct metastatic steps (Fig. 5).
Initial formation of pro-metastatic cells predisposed to
successful accomplishment of metastatic cascade is com-
monly associated with epithelial–mesenchymal transition
(EMT)— a morphological transformation necessary for
escape from the primary tumor and subsequent invasion
and metastatic growth. As discussed above, the mir-200c
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family is a well-known regulator of this mechanism
through targeting of the TGF-beta pathway [66–69].
Upstream modulators of ZEB1 and mir-200c expression
such as WASF3 and OSM have also been identified to play
a role in EMT progression and tumor metastases [70, 71].
Another prominent regulator of EMT is mir-29c, which is
up-regulated in oligometastatic patient samples and found
to also suppress EMT [72]. Finally, the most highly dif-
ferentially expressed micro-RNA in the pulmonary oligo-
metastatic samples, mir-655, has recently shown to target
ZEB1 and TGFBR2, resulting in similar inhibition of EMT
[73]. These data suggest that limited metastatic dissemi-
nation seen in oligometastatic patients may partially
depend on the control of EMT in the primary tumors
(Fig. 5).
Several miRNAs over-expressed in oligometastatic
samples have been shown to inhibit tumor cell adhesion
and migration. Though these miRNAs have varied targets,
their effects converge on mechanisms that are essential to
regulation of the cell cytoskeleton and interaction with the
extra-cellular matrix. Inhibition at this step can suppress
metastasis progression by preventing invasion through the
basement membrane in the primary tumor, or adhesion and
migration of circulating tumor cells that could otherwise
form metastases. Mir-125a is capable of inhibiting Fyn and
RhoA, kinases involved in promoting cell adhesion and
invasion through cytoskeletal re-arrangements and integrin
signaling [74]. Mir-363 has similar effects on
neuroblastoma cells and squamous cell carcinomas,
inhibiting invasion in vitro and metastasis in vivo partly
through suppression of podoplanin, a regulator of adhesion
and cytoskeletal structure [75]. Similar findings have been
observed in micro-RNAs up regulated in the pulmonary
oligometastatic samples. Mir-485 can inhibit breast cancer
migration, in addition to inhibition of colony formation
in vitro [76]. Mir-296 inhibits Scrib, a regulator of cell
motility, thus inhibiting growth in vivo, and repression of
this micro-RNA increases tumor invasiveness in vitro [77].
Invasion and adhesion to extracellular matrix is an essential
mechanism for metastasis development, and inhibition of
this step may result in the low total metastatic burden
observed in oligometastases by preventing colonization of
distant organs by circulating tumor cells (Fig. 5).
Finally, regulation of proliferation may be critical on the
late stages of metastatic cascades, leading to successful
colonization (Figs. 2, 5, Table 1). Several micro-RNAs
found to be up-regulated in both the SBRT trial and pul-
monary resection oligometastases groups are implicated in
such regulation. These include, mir-125a & b, mir-29c,
mir-133a, mir-193a, mir-331, mir-329 and mir-502
(Table 1) [78–85].The ability of these oligomiRs to inhibit
tumor growth is mediated by direct targeting of transcrip-
tion factors, including the E2F family and cell-checkpoint
proteins such as Cyclins D1, D2 and E1 in a variety of
carcinoma types. Cyclin pathways, especially Cyclin D1
and its downstream effectors CDK4 and CDK6, represent
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important targets of tumor-suppressing micro-RNAs.
Though the majority of known cell-cycle suppressing
micro-RNAs appear to inhibit progression through G1, a
few ‘‘oncomir’’ families have been identified that suppress
key inhibitors of the cyclin/CDK complexes, p21 and p27
[86, 87]. Tumor cell growth inhibition through cell-cycle
arrest may be a significant mechanism of the formation of
locally confined slow-growing oligometastases that are
amenable to treatment with localized therapy or resection.
Conclusion
Oligometastasis is a unique phenotype observed in some
cases of metastatic cancer. This type of tumor spread is
amenable to localized therapy including radiotherapy and
resection, resulting in improved outcomes compared to
patients with poly-metastatic disease. Analysis of patients’
tumor samples in two different datasets revealed differential
micro-RNA expression profiles correlating with metastasis
progression, regardless of primary tumor histology. Many
micro-RNAs identified in these experiments were up-regu-
lated in oligometastatic lesions and were associated with
tumor-suppressive functions. Such ‘‘oligomiRs’’ may be
involved in regulation of oligometastatic phenotype during
multistep process of metastases development. Biological
effects of oligomiRs identified in both datasets substantially
overlapped and converged on cell proliferation, migration,
adhesion and EMT. These functions are consistent with
continuous interactions of the tumor cells with the host
microenvironment during dissemination of metastatic cells
from the primary tumor to distant sites. The ability to derive
microRNA signatures from oligo/polymetastases, combined
with an understanding of the pathways regulated by these
Table 1 Known functions and down-stream targets of oligomiRs detected in clinical databases of oligometastatic patients







Mir-655 Surgery Suppressor EMT TGFBR2,ZEB1 [88]
mir-154 Surgery Suppressor Proliferation, motility, cell cycle, EMT TLR2, HMGA2, CCND2 [89–91]
mir-329 Surgery Suppressor Proliferation E2F1 [84]
mir-330 Surgery Mixed Proliferation, invasion, cell cycle,
adhesion, apoptosis
SP1, CDC42, SH3GL2 [92, 93]
mir-485 Surgery Suppressor Proliferation, migration MAT1A [76]
mir-380 Surgery Oncomir Proliferation, cell cycle p53 [94]
mir-298 Surgery Suppressor Drug sensitivity P-gp [95]
mir-153 Surgery Mixed Proliferation, apoptosis, drug resistance PTEN, FOXO3a, FOXO1 [96–98]
mir-296 Surgery Mixed Proliferation, cell cycle, apoptosis, drug
resistance, angiogenesis
ICAM1, CDX1, EAG1, Scrib,
HMGA1, HGS
[99–102]
mir-448 Surgery Suppressor EMT SATB1 [103]
mir-133a Surgery Suppressor Invasion, proliferation FSCN1, PNP, TALGN2 [104–106]
mir-328 Both Suppressor Invasion, drug resistance, cytokinesis,
migration, cell cycle, proliferation,
ECM degradation
ABCG2, MMP16, KIF23, PTPRJ [78, 107–110]
mir-502 Both Suppressor Proliferation, cell cycle Rab1B [85]
miR-199b-5p Both Suppressor Proliferation, drug resistance, invasion HER2, HES1 [111–113]
miR-125a-3p SBRT Suppressor Invasion, proliferation, apoptosis, cell
cycle arrest




miR-140-5p SBRT Suppressor EMT, proliferation TGFBR1, FGF9 [119]
miR-29c-3p SBRT Suppressor Proliferation, invasion, adhesion,
angiogenesis, drug resistance, apoptosis,
cell cycle arrest
MMP2, ITGB1, SIRT1, TIAM1,
TNFAIP3, CCNE1, p85, CDC42
[80, 120–124]
miR-489 SBRT Suppressor Proliferation PTPN11 [125]
miR-331-5p SBRT Suppressor Cell cycle E2F1 [83]
miR-193a-3p SBRT Suppressor Apoptosis, proliferation, EMT, drug
resistance, cell cycle
MCL1, EGFR, PLAU, KRAS,
p73, E2F6
[82, 126–129]
miR-363-3p SBRT Mixed EMT, invasion, proliferation MBP1, PDPN [75, 130, 131]
Functions that are up-regulated by a micro-RNA are italicized
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oligoMirs, may help identify patients with oligometastatic
progression with more accuracy than current clinical pre-
dictions. An understanding of the biologic basis of olig-
ometastases has the potential to improve patient care through
diagnostics and therapeutics. In addition, exploration of the
functions of microRNAs linked to oligometastases may give
more insight into the underlying mechanisms of metastatic
progression and reveal new previously unidentified targets
for future therapy.
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